Karin Ribi1, Weixiu Luo2, Barbara A Walley3, Harold J Burstein4, Jacquie Chirgwin5,6, Rafat H Ansari7, Muhammed Salim8, Andre van der Westhuizen6,9, Ehtesham Abdi10, Prudence A Francis6,11, Stephen Chia12, Vernon J Harvey13, Anita Giobbie-Hurder2, Gini F Fleming14, Olivia Pagani15, Angelo Di Leo16, Marco Colleoni17, Richard D Gelber2,18,19, Aron Goldhirsch20,21, Alan S Coates20,22, Meredith M Regan2,18, Jürg Bernhard20,23. 1. International Breast Cancer Study Group (IBCSG) Coordinating Center, Effingerstrasse 40, 3008, Bern, Switzerland. karin.ribi@ibcsg.org. 2. IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA. 3. University of Calgary and Canadian Cancer Trials Group, Calgary, AB, Canada. 4. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 5. Box Hill and Maroondah Hospitals, Monash University, Clayton, VIC, Australia. 6. Breast Cancer Trials Australia & New Zealand, University of Newcastle, Callaghan, Australia. 7. Norther Indiana Cancer Research Consortium, South Bend, USA. 8. Allan Blair Cancer Center, Regina, SK, Canada. 9. Calvary Mater Newcastle Hospital, Waratah, NSW, Australia. 10. The Tweed Hospital, Griffith University Gold Coast, Tweed Heads, NSW, Australia. 11. Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Australia. 12. BCCA-Vancouver Cancer Center, Vancouver, BC, Canada. 13. Auckland City Hospital, Auckland, New Zealand. 14. The University of Chicago Medical Center, Chicago, IL, USA. 15. Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), Lugano Viganello, Switzerland. 16. Hospital of Prato-AUSL Toscana Centro and International Breast Cancer Study Group, Prato, Italy. 17. IEO, European Institute of Oncology IRCCS, Milan, Italy. 18. Harvard Medical School, Harvard University, Boston, MA, USA. 19. Harvard TH Chan School of Public Health, Frontier Science and Technology Research Foundation, Boston, MA, USA. 20. International Breast Cancer Study Group (IBCSG) Coordinating Center, Effingerstrasse 40, 3008, Bern, Switzerland. 21. MultiMedica, Milan, Italy. 22. University of Sydney, Sydney, Australia. 23. Bern University Hospital, Inselspital, Bern, Switzerland.
Abstract
PURPOSE: Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials. METHODS: A subset of patients enrolled in TEXT and SOFT completed global and symptom-specific quality-of-life indicators, CES-Depression and MOS-Sexual Problems measures at baseline, six, 12 and 24 months. Mixed models tested the association of changes in treatment-induced symptoms (baseline to 6 months), depression at 6 months, and age at randomization with changes in sexual problems over 2 years. RESULTS: Sexual problems increased by 6 months and persisted at this level. Overall, patients with more severe worsening of vaginal dryness, sleep disturbances and bone or joint pain at 6 months reported a greater increase in sexual problems at all time-points. Depression scores were significantly associated with sexual problems in the short-term. All other symptoms had a smaller impact on sexual problems. Age was not associated with sexual problems at any time-point. CONCLUSION: Among several key symptoms, vaginal dryness, sleep disturbance, and bone and joint pain significantly predicted sexual problems during the first 2 years. Early identification of these symptoms may contribute to timely and tailored interventions.
PURPOSE:Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials. METHODS: A subset of patients enrolled in TEXT and SOFT completed global and symptom-specific quality-of-life indicators, CES-Depression and MOS-Sexual Problems measures at baseline, six, 12 and 24 months. Mixed models tested the association of changes in treatment-induced symptoms (baseline to 6 months), depression at 6 months, and age at randomization with changes in sexual problems over 2 years. RESULTS: Sexual problems increased by 6 months and persisted at this level. Overall, patients with more severe worsening of vaginal dryness, sleep disturbances and bone or joint pain at 6 months reported a greater increase in sexual problems at all time-points. Depression scores were significantly associated with sexual problems in the short-term. All other symptoms had a smaller impact on sexual problems. Age was not associated with sexual problems at any time-point. CONCLUSION: Among several key symptoms, vaginal dryness, sleep disturbance, and bone and joint pain significantly predicted sexual problems during the first 2 years. Early identification of these symptoms may contribute to timely and tailored interventions.
Entities:
Keywords:
Breast cancer; Depression; Endocrine treatment; Sexual problems; Treatment-induced symptoms
Authors: Leticia Aptecar; Frederic Fiteni; Marta Jarlier; Stephanie Delaine; Violaine Guillerme; William Jacot; Veronique D'Hondt Journal: Breast Cancer Res Treat Date: 2021-01-15 Impact factor: 4.872
Authors: Neha Verma; Amanda L Blackford; Elissa Thorner; Jennifer Lehman; Claire Snyder; Vered Stearns; Karen Lisa Smith Journal: Breast Cancer Res Treat Date: 2022-10-05 Impact factor: 4.624
Authors: Angelique Bobrie; Marta Jarlier; Aurore Moussion; William Jacot; Veronique D'Hondt Journal: Support Care Cancer Date: 2022-01-14 Impact factor: 3.359
Authors: Karen Lisa Smith; Neha Verma; Amanda L Blackford; Jennifer Lehman; Kelly Westbrook; David Lim; John Fetting; Antonio C Wolff; Daniela Jelovac; Robert S Miller; Roisin Connolly; Deborah K Armstrong; Raquel Nunes; Kala Visvanathan; Carol Riley; Katie Papathakis; Nelli Zafman; Jennifer Y Sheng; Claire Snyder; Vered Stearns Journal: NPJ Breast Cancer Date: 2022-04-21